Kornimate/medical-research-clean huggingface dataset:
efficacy of proprietary cherry juice blend in osteoarthritis of the knee

Conditions: Osteoarthritis

Summary: the primary purpose of this research study is to test the ability of a proprietary cherry juice blend to be helpful in the treatment of osteoarthritis (oa) of the knee.

the primary objective is to determine if the proprietary tart cherry juice blend improves the pain and function in persons with knee osteoarthritis. a secondary objective is to ascertain if the blend lowers serum uric acid. this is a prospective double blind, placebo controlled cross-over study. the study will be performed in the philadelphia va medical center 1 south rheumatology clinic with patients meeting acr criteria for kellgren grade 2-3 knee osteoarthritis and 4-9 pain severity on a vas. fifty patients will be studied with each having 5 visits. subjects will take either the proprietary cherry blend or placebo for 6 weeks and then switch. womac pain and function will be the primary outcome with acetaminophen use, walking time and serum uric acid as secondary outcomes.

Eligibility criteria:
inclusion criteria: * subject is capable of giving informed consent. * subject is over 18 years and less than 80 years * subject has mild to moderate osteoarthritis of the knee based on all of the following 3: 1. meets clinical acr criteria 2. kellgren score of 2-3 on a standing knee x-ray within previous 24 months 3. vas pain score of 4-9 at screening visit exclusion criteria: * rheumatoid arthritis or other systemic inflammatory condition * chronic pain syndrome (fibromyalgia) * corticosteroid medication in last 2 months, either intra-articular or oral * intra-articular injections of hyaluronic acid in last 9 months * pregnant women (weight gain might confound degree of knee pain) * diabetes * inability to discontinue prescription medication for arthritis * unstable medical conditions that would likely prevent the subject from completing the study * food allergies - cherries, apples

Keywords: osteoarthritis gout pain uric acid tart cherry alternative medicine knees
mayo acute stroke trial for enhancing recovery

Conditions: Ischemic Stroke

Summary: this study involves treating patients that have suffered an acute ischemic stroke with the medication donepezil (aricept ®). the hypothesis is that taking donepezil (fda-approved for the treatment of alzheimer's disease) for the first 90 days following a stroke enhances recovery.

we hypothesize that donepezil (5 mg per day, titrated up to 10 mg per day as tolerated) will enhance recovery following stroke by improving attention, learning and memory thereby enhancing rehabilitation. the null hypothesis is that the probability of a favorable outcome among post-stroke donepezil users is equal to that observed among similar participants in an existing national institutes of neurological disorders and stroke (ninds) resource, the phase iii clinical trial of tissue plasminogen activator (tpa) for acute ischemic stroke. the ninds tpa stroke trial has been used as historical control data in pilot trials of reperfusion and neuroprotection. the master trial will be a multicenter, single-arm ninds recominant tpa trial-controlled, modified 2-stage adaptive clinical trial set in 2 tertiary care hospitals in the united states. participants will be men and women with acute (\< 24 hours of onset of symptoms) ischemic stroke. a favorable outcome will be defined as national institutes of health stroke scale (nihss) values of 0 or 1 at 90 days post-stroke.

Eligibility criteria:
inclusion criteria: * definite or probable acute ischemic cerebrovascular syndrome (aics), as defined by kidwell et al (stroke. 2003;34:2995-8). * experimental treatment started within 24 hours of onset of symptoms. * age ≥ 18 years. * ability and willingness to return for follow-up visits. * willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period. * living in independent or semi-independent living situation before the stroke. * fluent in english before the stroke. * provides written informed consent. * near visual acuity of at least 20/200 in at least one eye. * auditory acuity of at least having the ability to detect finger rubbing in at least one ear. exclusion criteria: * parkinson's disease or restless leg syndrome. * partial or generalized seizures. * no acute decompensated heart failure * routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (cpap) for obstructive sleep apnea remain eligible. * gastrointestinal or genitourinary surgery within 1 month of screening. * gastrointestinal bleeding. * syncope or symptomatic bradycardia. * creatinine ≥ 3.5 mg/dl or requiring dialysis. * peptic ulcer disease. * asthma. * tracheostomy or endotracheal intubation. * taking donepezil or other acetylcholinesterase inhibitor at screening.

Keywords: ischemic stroke treatment recovery donepezil aricept
neoadjuvant platinum-based chemoradiation therapy for locally advanced triple negative breast cancer

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine whether platinum-based chemotherapy (either cisplatin or carboplatin), when given with radiation therapy prior to surgery, is effective in improving response to treatment in triple negative breast cancer patients. this treatment is being studied in this type of breast cancer because it does not respond well to commonly used treatments such as tamoxifen or herceptin.


Eligibility criteria:
inclusion criteria: * patient must be \> or = 18 years of age * patient must be female * patient must have primary invasive ductal breast adenocarcinoma that either: 1. is newly diagnosed, without previous systemic treatment or 2. has failed to respond to \< or = 4 cycles of neoadjuvant anthracycline based therapy as assessed by clinical exam or imaging studies (mammogram, ultrasound or breast mri). * patient's tumor must be classified as clinically stage t2, t3, or t4 with any n (nx, n0, n1, n2, or n3) prior to any neoadjuvant treatment. * patient must have an ecog performance status of \< or = 1. * patient must have adequate organ function defined as: 1. renal function: 1. crcl ≥ 60 ml/min for patients receiving cisplatin 2. crcl ≥ 30 ml/min for patients receiving carboplatin. 2. liver function: 1. alt, ast, alk phos \< or = 1.5 x upper limit of institutional normal. 2. bilirubin \< or = 1.5 x upper limit of institutional normal. 3. normal left ventricular function (lvef \> 50%) by muga or echo. 4. hematologic: 1. absolute neutrophil count \> or = 1500/mcl 2. platelets \> or = 100,000/mcl 3. hemoglobin \> or = 8.0 g/dl * patient must be able and willing to sign informed consent document. exclusion criteria: * patient must not have evidence of distant metastasis present by ct, bone scan, or pet-ct. if the bone scan or ct scans demonstrate indeterminate lesions, the nature of these lesions should be further clarified by additional testing such as pet or mri at the discretion of the treating physician. * patients having received neoadjuvant anthracycline based therapy must undergo restaging to exclude distant metastases prior to enrollment. * patient must not have had any prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated with at least greater than 5 years disease free survival. * patient's tumor must not express the following biomarkers or must have allred score \< 4 for: estrogen receptor, progesterone receptor, and is not her2/neu amplified. * women of child bearing potential may not be currently pregnant or breastfeeding at time of registration and must agree to use adequate contraception. * patient must have \> or = grade 2 peripheral neuropathy. * patient must have a known hearing impairment (hearing loss or severe tinnitus). hearing test will be performed at the discretion of the treating physician. * patient must not have been previously treated with cisplatin or carboplatin for any condition.
increasing breast cancer screening in chinese immigrants

Conditions: Screening Mammogram

Summary: the long-term goal of this research is to increase breast cancer screening rates in nyc chinese immigrants. the researchers plan to accomplish this objective by developing and testing a culturally- and linguistically-adapted witness project program for chinese immigrants. to inform the intervention development, the study team will identify barriers and facilitators to breast cancer screening in chinese immigrants through individual qualitative interviews. a total of 156 participants will be recruited during the entire study. in aim 1 which started in july 2021, 60 women were recruited for in-depth interviews to assess their breast cancer knowledge, perceived barriers and benefits/risks to completing mammography, perceived susceptibility to breast cancer, fatalism, screening intention, acculturation, language preference, and health literacy. in aim 2, 96 women will be recruited to participate in the pilot testing of the intervention. recruitment will take place at community sites that serve chinese immigrants in new york city. enrollment for aim 2 is anticipated to start in march of 2022.


Eligibility criteria:
inclusion criteria: * ≥ 40 years of age * female * born in china * read and speak cantonese, mandarin, or english exclusion criteria: - none

Keywords: breast cancer screening health education chinese immigrant health disparities
outdoor allergen exposure, sensitivity, and acute asthma

Conditions: Asthma

Summary: to examine the role of outdoor pollen grains and fungal spores in the exacerbation of asthma and to produce forecasting models to predict days of high concentration.

asthma is a growing problem, and outdoor allergens play a role in exacerbation of many cases. a clearer understanding of this role and its magnitude, and a means of controlling the effects of outdoor allergen exposures is needed. we propose poisson time-series and conditional panel studies to test these hypotheses: 1) the incidence of acute asthma attacks, as measured by urgent care inhalation treatments and hospitalizations for asthma, has a dose-dependent relationship with exposure to specific outdoor allergens; 2) specific sensitization to outdoor allergens is a risk factor for having an acute attack; and 3) exposure conditions that lead to acute asthma attacks can be forecast, creating an opportunity to reduce asthma morbidity and mortality ny targeting pretreatment and/or exposure controls.

Eligibility criteria:
must be a member of the fallon hmo and be treated for acute asthma exacerbation.

Keywords: asthma allergens
effect of folic acid, vitamin b6 and vitamin b12 in diabetic retinopathy

Conditions: Non Proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy

Summary: homocysteine, a well-known inducer of vascular endothelial cell damage has been associated with extracellular matrix changes. many studies demonstrated that high levels of this aminoacid in diabetic patients increases significantly the risk of the development of this pathology. this study has been undertaken to investigate the role of homocysteine and its cofactors (folic acid, vitamin b6 and b12) during the progression of the diabetic retinopathy.


Eligibility criteria:
inclusion criteria: * diabetic patients with proliferative and non proliferative retinopathy exclusion criteria: * patients with chronic liver disease patients with kidney disease.
norwegian psychomotor physiotherapy in patients with long-lasting musculoskeletal pain.

Conditions: Physical Disability

Summary: the aim is to examine the effect of norwegian psychomotor physiotherapy (npmp) in employees with long-lasting musculoskeletal pain compared to employees receiving cognitive patient education in combination with active individual physiotherapy (cope-pt) on pain, function, quality of life and sick-leave

the npmp is based on the assumption that patients with long-lasting problems, physical and/or psychological, may react with general aberrations related to posture, respiration, and movements, as well as with muscular tension and skin changes. employees with long lasting musculoskeletal pain problems, working in the municipality of bergen, will be invited to participate in an randomized clinical trial (rct), and randomized to either receive norwegian psychomotor physiotherapy (npmp) or a series of cognitive patient education in combination with active individual physiotherapy (cope-pt). the aim is to examine the effect of npmp compared to those receiving cope-pt on pain, function, quality of life and sick-leave.

Eligibility criteria:
inclusion criteria: * patients with neck,shoulder and/or widespread pain * pain (≥ 3 numeric pain rating scale (nprs) * functional problems measured with orebro musculoskeletal pain screening questionnaire (ompsq), neck disability index (ndi) and/or shoulder pain and disability inventory (spadi)-been sick-listed for 4-8 weeks, or on the brink of becoming sick-listed, or having had residual neck- and shoulder complaints problems during the last two years with several short-term sick-leaves. * =/6 american college of rheumatology (acr) tender points, * reduced relaxation and flexibility from the global physiotherapy examination (gpe) exclusion criteria: * sick-listed \> 6 months

Keywords: musculoskeletal disorders psychosomatic pain
combined transcranial magnetic stimulation and therapy for mtbi related headaches

Conditions: TBI (Traumatic Brain Injury); Headache; Depression

Summary: this study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rtms) and telehealth based therapy in helping manage mild traumatic brain injury (mtbi) related headaches. the investigators hypothesize that active rtms combined with telehealth therapy will provide marked reduction in mtbi related headaches and symptoms in comparison to their placebo counterparts.

this study will be enrolling a total of 240 veterans or active military over a 4 year period at the va san diego healthcare system (vasdhs). participants will be randomized into one of four groups: group a: active rtms with telehealth headache management therapy group b: active rtms with telehealth headache education control group c: sham rtms with telehealth headache management therapy group d: sham rtms with telehealth headache education control individual participation will consist of 19 visits to the vasdhs and 11 telehealth sessions over the course of 6-7 months. the in person visits will be divided into the following phases: 1. pre-treatment assessments phase (weeks 1-2) which consists of visit 1 (screening visit) and visit 2 (baseline assessments with mri scan); 2. induction treatment phase (weeks 3-4) consists of visits 3-12 (10 weekday neuronavigation guided rtms sessions at \>24 and \<72 hours apart); and 3. post-treatment assessments and maintenance treatment phase (weeks 5-24) consists of 4 initial biweekly post-induction treatment assessments and maintenance treatments (visits 13-16)) and two additional monthly post-induction assessments and maintenance treatments (visits 17-18) and one final study visit (visit 19). eight weekly telehealth therapy/education sessions will be conducted from week 3 to 10 with additional three bolster sessions at 4 weeks apart. during the baseline and follow up visits, assessments will be conducted to evaluate headaches, neurobehavioral symptoms, depressive symptoms, post-concussion symptoms, and quality of life.

Eligibility criteria:
inclusion criteria: 1. mild traumatic brain injury (mtbi) 2. chronic headaches \> 3 months after injury 3. aged 18-65 4. no prior tms treatment 5. persistent headaches with an intensity \> 30 / 100 6. no history of daily headache prior to mtbi exclusion criteria: 1. pregnant 2. pacemaker or any metal in body that would prevent mri 3. history of dementia or major psychiatric disease, such as bipolar disorder or schizophrenia 4. presence of any other chronic neuropathic pain states 5. history of seizure 6. pending litigation 7. can't understand english 8. history of chronic headache like migraine prior to mtbi 9. evidence in chart of exacerbation of depressive/anxiety symptoms, active substance dependence, suicidal intent or attempt within previous month

Keywords: rtms transcranial magnetic stimulation therapy
real world study on erlotinib/gefitinib combined with bevacizumab in advanced non-aquamous non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: this study aims to explore the efficacy and safety of erlotinib/gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with egfr mutation, explore new drug resistance mechanisms under the a+t regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. the role of disease progression risk.

a retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (nsclc) with egfr mutation positive treated with a+t was conducted to observe the efficacy and safety of a+t regimen in the real world. exploratory research contents are as follows: 1. consistency between tissue gene test (ngs) and plasma gene test (ngs) at the initial diagnosis; 2. consistency between tissue gene test (ngs) and plasma gene test (ngs) at the progression of a + t treatment; 3. new drug resistance mechanism of a + t treatment; 4. plasma dynamics during a + t treatment. detection (the first efficacy evaluation and a blood sampling before imaging pd) exploration and imaging progress sequence; 5. plasma large panel dynamic drive gene mutation spectrum analysis to build disease progression risk model.

Eligibility criteria:
inclusion criteria: * egfr mutation(19del/l858r) * advanced non-saquamous non-small cell lung cancer * primary treatment of first diagnosis * performance status（0-1) exclusion criteria: * other genes mutation * saquamous

Keywords: non-small cell lung cancer bevacizumab erlotinib/gefitinib egfr mutation positive
rectal cancer surgery without mechanical bowel preparation

Conditions: Patients With Rectal Cancer

Summary: the aim of this controlled multicentric study is to assess rectal cancer surgery with sphincter preservation without pre operative mechanical bowel preparation

preoperative mechanical bowel preparation (mbp) (i.e. including oral laxatives, retrograde enemas and/or oral diet before surgery) is the standard practice in colorectal surgery. the importance of mbp in preventing anastomotic leakage and infectious morbidity after elective colorectal surgery has been a dogma among surgeons for many years. the main reason is the belief that postoperative complications is related to septic bowel content. however, there is a paucity of scientific evidence demonstrating the efficacy of this practice in reducing morbidity. moreover, potential disadvantages of mbp include the requirement for a longer preoperative duration of admission before surgery, its time consuming nature, being expensive and unpleasant for the patient and expose the early population to the particular risk of fluid and electrolyte imbalance .at least eight randomized clinical trials and two meta-analyses failed to show any superiority of mbp in colorectal surgery. on the contrary, they demonstrated that preparation might lead to an increased rate of septic complications. such initial dates lead surgeons to re-evaluate their current clinical practice in colonic surgery. but to dates, these findings cannot finally be applied to rectal surgery because of insufficient dates. to date, no study about mbp was specifically devoted to rectal surgery. moreover, it is currently admitted that the risk of septic complications following rectal resection, as a result of the well-known risk factors, is higher than after colonic preparation. it is the reason why most of the colorectal surgeons consider that a no preparation regimen in rectal cancer surgery could represent an additive risk factor for postoperative morbidity.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patient with rectal cancer without any metastasesrectal excision with sphincter preservation with colorectal or coloanal anastomosis (with or without temporary ileostomy) exclusion criteria: * stage iv disease * comorbidity with post operative infectious risk corticoids,immunodeficiency, crohn's disease, ulcerative colitis ...) * abdominoperineal resection * emergency surgery

Keywords: rectal cancer sphincter preservation mechanical bowel preparation post operative morbidity anastomotic leakage
trial to investigate immune responses elicited by a liquid formulation of influenza virus vaccine, trivalent, types a & b, live cold adapted (caiv-t) in healthy adults

Conditions: Influenza

Summary: to perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types a and b, live, cold-adapted (liquid caiv-t; wyeth lederle vaccines, marietta, pa).


Eligibility criteria:
inclusion criteria: * who are between 18 to 64 years of age. subject must be at least 18 years of age and no older than 64 years of age at the time informed consent is obtained; * eligible female subjects, who are of childbearing potential, who have a negative urine pregnancy test results prior to study vaccination. females who are surgically sterile or post-menopausal do not require pregnancy testing. * who are determined by medical history, physical examination and clinical judgement to be eligible for this study. subjects with stable pre-existing disease, defined as disease not requiring change in therapy or hospitalization within 12 weeks before receipt of study vaccination will be eligible. * who have provided written informed consent after the nature of the study has been explained; * who, will be available for two month duration of the trial (from enrollment to study completion); * who can be reached by study staff for the post-vaccination contact \[telephone, clinic or home visit\] exclusion criteria: * who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period * with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents; * who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study; * have an immunosuppressed or an immunocompromised individual living in the same household; * with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo; * who were administered any live virus vaccine within one month prior to enrollment; * for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study; * who, received a dose of influenza treatment (commercial or investigational) one month prior to enrollment. the prophylactic use of influenza antivirals is not permitted. * who receive any influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment; * with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; note: a pregnant household member is not considered a contraindication to enrollment.